ATE111744T1 - Pharmazeutische zusammensetzungen von rekombinantem beta-interferon und herstellungsverfahren. - Google Patents
Pharmazeutische zusammensetzungen von rekombinantem beta-interferon und herstellungsverfahren.Info
- Publication number
- ATE111744T1 ATE111744T1 AT87115693T AT87115693T ATE111744T1 AT E111744 T1 ATE111744 T1 AT E111744T1 AT 87115693 T AT87115693 T AT 87115693T AT 87115693 T AT87115693 T AT 87115693T AT E111744 T1 ATE111744 T1 AT E111744T1
- Authority
- AT
- Austria
- Prior art keywords
- pharmaceutical compositions
- manufacture
- beta interferon
- recombinant beta
- ionic polymeric
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92342386A | 1986-10-27 | 1986-10-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE111744T1 true ATE111744T1 (de) | 1994-10-15 |
Family
ID=25448670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT87115693T ATE111744T1 (de) | 1986-10-27 | 1987-10-26 | Pharmazeutische zusammensetzungen von rekombinantem beta-interferon und herstellungsverfahren. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0270799B1 (de) |
| JP (1) | JPS63179833A (de) |
| AT (1) | ATE111744T1 (de) |
| AU (2) | AU8019187A (de) |
| CA (1) | CA1294215C (de) |
| DE (1) | DE3750574T2 (de) |
| DK (1) | DK563487A (de) |
| FI (1) | FI95002C (de) |
| NO (1) | NO175704C (de) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5183746A (en) * | 1986-10-27 | 1993-02-02 | Schering Aktiengesellschaft | Formulation processes for pharmaceutical compositions of recombinant β- |
| US4961969A (en) * | 1987-05-11 | 1990-10-09 | Cetus Corporation | Process for recovering microbially produced interferon-β |
| US5151265A (en) * | 1987-11-03 | 1992-09-29 | Genentech, Inc. | Gamma interferon formulation |
| US5004605A (en) * | 1987-12-10 | 1991-04-02 | Cetus Corporation | Low pH pharmaceutical compositions of recombinant β-interferon |
| IL89662A (en) * | 1989-03-19 | 1997-11-20 | Interpharm Lab Ltd Kiryat Weiz | Pharmaceutical compositions comprising interferon-beta |
| US5843693A (en) * | 1989-08-16 | 1998-12-01 | Chiron Corporation | Assay method for screening for inhibitors of proTNF conversion |
| US5998378A (en) * | 1989-08-16 | 1999-12-07 | Chiron Corporation | Compositions for the inhibition of TNF hormone formation and uses thereof |
| US6586222B1 (en) | 1989-08-16 | 2003-07-01 | Chiron Corporation | Recombinant PR-3 and compositions thereof |
| US20030171292A1 (en) | 1992-06-01 | 2003-09-11 | Creasey Abla A. | Method for using lipoprotein associated coagulation inhibitor to treat sepsis |
| US6063764A (en) * | 1992-06-01 | 2000-05-16 | Washington University & Chiron Corp. | Method for using lipoprotein associated coagulation inhibitor to treat sepsis |
| EP0672144A1 (de) * | 1992-10-20 | 1995-09-20 | Chiron Corporation | Interleukin-6-receptor-antagonisten |
| AU709054B2 (en) | 1994-03-07 | 1999-08-19 | Chiron Corporation | Compositions for the inhibition of TNF formation and uses thereof |
| IT1272252B (it) | 1994-05-16 | 1997-06-16 | Applied Research Systems | Formulazioni liquide di interferone beta |
| US5556771A (en) * | 1995-02-10 | 1996-09-17 | Gen-Probe Incorporated | Stabilized compositions of reverse transcriptase and RNA polymerase for nucleic acid amplification |
| GB9506051D0 (en) * | 1995-03-24 | 1995-05-10 | Univ Singapore | Gene expression |
| US20030190307A1 (en) | 1996-12-24 | 2003-10-09 | Biogen, Inc. | Stable liquid interferon formulations |
| JP4293497B2 (ja) | 1997-09-23 | 2009-07-08 | レントシュレール ビオテクノロジー ゲー・エム・ベー・ハー | インターフェロン−β液状組成物 |
| US6465425B1 (en) | 2000-02-10 | 2002-10-15 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins |
| US7544354B2 (en) | 2000-10-27 | 2009-06-09 | Novartis Vaccines And Diagnostics | Methods of protein purification and recovery |
| IL155788A0 (en) | 2000-11-07 | 2003-12-23 | Chiron Corp | Stabilized interferon compositions |
| US7101693B2 (en) | 2001-09-07 | 2006-09-05 | Brigham Young University | Plasticized hydrophilic glasses for improved stabilization of biological agents |
| CN1604790A (zh) | 2001-10-15 | 2005-04-06 | 希龙公司 | 通过施用组织因子途径抑制剂(tfpi)治疗严重性肺炎 |
| US20070218060A1 (en) | 2003-11-04 | 2007-09-20 | Chiron Corporation | Use of Antagonist Anti-Cd40 Monoclonal Antibodies for Treatment of Multiple Myeloma |
| PT1680141E (pt) | 2003-11-04 | 2010-12-20 | Novartis Vaccines & Diagnostic | Métodos terapêuticos para tumores sólidos que expressam o antigénio de superfície celular cd40 |
| DK1682177T3 (da) | 2003-11-04 | 2010-11-01 | Novartis Vaccines & Diagnostic | Anvendelse af antagonist-anti-CD40-antistoffer til behandling af kronisk lymfocytisk leukæmi |
| JP4746552B2 (ja) | 2003-11-04 | 2011-08-10 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 自己免疫疾患および炎症性疾患ならびに臓器移植拒絶の処置のためのアンタゴニスト抗ｃｄ４０抗体の使用 |
| EP1844815B1 (de) | 2003-11-04 | 2011-09-14 | Novartis Vaccines and Diagnostics, Inc. | Kombinationstherapie von anti-CD20 und anti-CD40 Antikörpern zur Behandlung von B-Zell-bedingtem Krebs |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| WO2012075111A1 (en) | 2010-11-30 | 2012-06-07 | Novartis Ag | Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers |
| EP2646459B1 (de) | 2010-12-02 | 2020-01-08 | Bionor Immuno AS | Peptidgerüstentwurf |
| AU2012204955B2 (en) | 2011-01-06 | 2016-10-06 | Bionor Immuno As | Monomeric and multimeric immunogenic peptides |
| IN2014KN02769A (de) | 2012-06-06 | 2015-05-08 | Bionor Immuno As | |
| UA105278C2 (ru) | 2012-09-06 | 2014-04-25 | Інститут Біології Клітини Нан України | Способ получения каталитически активных антител (абзимов) с сиалидазной активностью |
| KR102279717B1 (ko) | 2013-04-23 | 2021-07-20 | 세다르스-신나이 메디칼 센터 | 형광단들로부터의 가시 광 이미지 및 적외선 광 이미지를 동시에 레코딩하기 위한 시스템들 및 방법들 |
| RU2682335C2 (ru) | 2014-01-17 | 2019-03-19 | Сидарс-Синай Медикал Сентр | Рецептор-направленные конструкции и их применение |
| KR102567244B1 (ko) | 2014-06-12 | 2023-08-16 | 세다르스-신나이 메디칼 센터 | 암을 치료하는 조성물 및 방법 |
| WO2016013751A1 (ko) | 2014-07-22 | 2016-01-28 | 주식회사 레모넥스 | 생리활성 물질 또는 단백질 전달용 조성물 및 이의 용도 |
| CN107106669A (zh) | 2014-11-04 | 2017-08-29 | 南加利福尼亚大学 | 用于治疗过度表达HIF‑1α的癌症的组合物和方法 |
| US10441644B2 (en) | 2015-05-05 | 2019-10-15 | The Regents Of The University Of California | H3.3 CTL peptides and uses thereof |
| WO2016179326A1 (en) | 2015-05-05 | 2016-11-10 | The Regents Of The University Of California | H3.3 ctl peptides and uses thereof |
| US11567078B2 (en) | 2015-08-31 | 2023-01-31 | Cedars-Sinai Medical Center | Blood cell biomarker for late onset Alzheimer's disease |
| KR20180103816A (ko) | 2016-02-09 | 2018-09-19 | 오토텔릭 엘엘씨 | 췌장암을 치료하기 위한 조성물과 방법 |
| KR20180103817A (ko) | 2016-02-09 | 2018-09-19 | 오토텔릭 엘엘씨 | 암을 치료하기 위한 조성물과 방법 |
| FI126979B (en) * | 2016-02-29 | 2017-09-15 | Faron Pharmaceuticals Oy | Lyophilized pharmaceutical formulation and use thereof |
| WO2018143787A1 (ko) | 2017-02-06 | 2018-08-09 | 주식회사 레모넥스 | 생리활성물질 전달체 |
| EP3578171A4 (de) | 2017-02-06 | 2020-12-30 | Lemonex Inc. | Träger eines physiologisch wirksamen wirkstoffs |
| US20210121493A1 (en) | 2017-07-25 | 2021-04-29 | Cedars-Sinai Medical Center | Methods for treating liver diseases |
| KR102152348B1 (ko) | 2017-09-05 | 2020-09-08 | 주식회사 레모넥스 | 세포 운명 조절용 조성물 |
| US11690799B2 (en) | 2018-04-19 | 2023-07-04 | Lts Lohmann Therapie-Systeme Ag | Microneedle system for applying interferon |
| MX2020011004A (es) * | 2018-04-19 | 2020-11-09 | Lts Lohmann Therapie Systeme Ag | Sistema de microagujas para la aplicacion de interferon. |
| CA3117386A1 (en) | 2018-11-08 | 2020-05-14 | Cedars-Sinai Medical Center | Use of clazakizumab to desensitize and improve renal transplantation in hla-sensitized patients |
| CA3121934A1 (en) | 2018-12-20 | 2020-06-25 | Cedars-Sinai Medical Center | Clazakizumab in the treatment of chronic antibody-mediated rejection of organ transplant |
| WO2021160887A1 (en) | 2020-02-14 | 2021-08-19 | Immunor As | Corona virus vaccine |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55102519A (en) * | 1979-01-31 | 1980-08-05 | Green Cross Corp:The | Stabilization of interferon |
| CA1190148A (en) * | 1981-10-13 | 1985-07-09 | Samuel S. Asculai | Interferon-containing compositions |
| JPS5910524A (ja) * | 1982-07-08 | 1984-01-20 | Toray Ind Inc | インタ−フエロン組成物およびその製造法 |
| US4992271A (en) * | 1982-09-23 | 1991-02-12 | Cetus Corporation | Formulation for lipophilic IL-2 proteins |
| US4462940A (en) * | 1982-09-23 | 1984-07-31 | Cetus Corporation | Process for the recovery of human β-interferon-like polypeptides |
| EP0107498B1 (de) * | 1982-10-25 | 1990-05-16 | Genentech, Inc. | Synergistische Humaninterferonaktivität |
| EP0150067A3 (de) * | 1984-01-23 | 1986-12-30 | Takeda Chemical Industries, Ltd. | Stabile Gamma-Interferon-Zusammensetzung |
| US4680175A (en) * | 1984-02-07 | 1987-07-14 | Interferon Sciences, Inc. | Interferon administration vehicles |
| US4606917A (en) * | 1984-10-03 | 1986-08-19 | Syntex (U.S.A) Inc. | Synergistic antiviral composition |
| JPS61277633A (ja) * | 1985-05-31 | 1986-12-08 | Toray Ind Inc | インタ−フエロン組成物 |
-
1987
- 1987-10-16 CA CA000549489A patent/CA1294215C/en not_active Expired - Lifetime
- 1987-10-26 AT AT87115693T patent/ATE111744T1/de not_active IP Right Cessation
- 1987-10-26 EP EP87115693A patent/EP0270799B1/de not_active Expired - Lifetime
- 1987-10-26 NO NO874445A patent/NO175704C/no not_active IP Right Cessation
- 1987-10-26 FI FI874706A patent/FI95002C/fi not_active IP Right Cessation
- 1987-10-26 DE DE3750574T patent/DE3750574T2/de not_active Expired - Lifetime
- 1987-10-27 DK DK563487A patent/DK563487A/da not_active Application Discontinuation
- 1987-10-27 JP JP62271604A patent/JPS63179833A/ja active Pending
- 1987-10-27 AU AU80191/87A patent/AU8019187A/en not_active Abandoned
-
1992
- 1992-02-03 AU AU10633/92A patent/AU659127B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| NO175704B (no) | 1994-08-15 |
| NO874445L (no) | 1988-04-28 |
| DE3750574D1 (de) | 1994-10-27 |
| FI95002B (fi) | 1995-08-31 |
| FI95002C (fi) | 1995-12-11 |
| DK563487A (da) | 1988-04-28 |
| AU1063392A (en) | 1992-03-19 |
| DE3750574T2 (de) | 1995-02-02 |
| NO874445D0 (no) | 1987-10-26 |
| EP0270799A1 (de) | 1988-06-15 |
| AU8019187A (en) | 1988-04-28 |
| CA1294215C (en) | 1992-01-14 |
| EP0270799B1 (de) | 1994-09-21 |
| FI874706A0 (fi) | 1987-10-26 |
| FI874706A (fi) | 1988-04-28 |
| JPS63179833A (ja) | 1988-07-23 |
| AU659127B2 (en) | 1995-05-11 |
| DK563487D0 (da) | 1987-10-27 |
| NO175704C (no) | 1994-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE111744T1 (de) | Pharmazeutische zusammensetzungen von rekombinantem beta-interferon und herstellungsverfahren. | |
| ATE74512T1 (de) | Pharmazeutische zusammensetzungen von rekombinanten interleukin-2 und herstellungsverfahren. | |
| ATE106247T1 (de) | Formulierung für rekombinantes beta-interferon, verfahren zur gewinnung und stabilisierung des beta-interferons und dessen verwendung. | |
| KR100656125B1 (ko) | 장기 안정화 제제 | |
| KR970706017A (ko) | 안정한 알파 인터페론 수용액 제형(Stable, aqueous alfainterfer on solution for mulations) | |
| ATE66817T1 (de) | Stabile formulierung biologisch aktiver proteine zur parenteralen injektion. | |
| DE68924491D1 (de) | Intrascheidenabgabe von aktiven Polypeptiden. | |
| LU88738I2 (fr) | Hormone Folliculo-Stimulante humaine recombinante (follitropine alpha) et ses dérivés pharmaceutiquement acceptables GONAL-F | |
| DK97987A (da) | Solubilisering af proteiner til farmaceutiske sam mensaetninger under anvendelse af polymerkonjugation | |
| ATE33503T1 (de) | Pharmazeutische und tiermedizinische praeparate von interleukin-2, in dem cystein-125 ausgetauscht worden ist (muteine), sowie deren herstellung. | |
| DK0388220T3 (da) | Præparater til vedvarende frigivelse af klorhexidin | |
| ATE194917T1 (de) | Flüssige beta-interferon formulierungen | |
| BR9202374A (pt) | Composicao implantavel para a administracao parenteral de uma quantidade essencialmente uniforme e continua de uma proteina,um peptideo ou polipeptideo biologicamente ativos,processo de elevar e manter elevados niveis no sangue de uma proteina,peptideo ou polipeptideo biologicamente ativos e processo para a preparacao da composicao implantavel | |
| DE3854290D1 (de) | Stabilisierung von therapeutisch wirksamen Proteinen in pharmazeutischen Zubereitungen. | |
| FR2684878B1 (fr) | Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation. | |
| DK0456153T3 (da) | Galeniske vandige formuleringer af erythopoietin og deres anvendelse |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| EELA | Cancelled due to lapse of time |